Seeking transpaRINcy for rituximab dosing in NMOSD

Lancet Neurol. 2020 Sep;19(9):716. doi: 10.1016/S1474-4422(20)30280-5.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aquaporin 4
  • Double-Blind Method
  • Humans
  • Immunologic Factors
  • Neuromyelitis Optica*
  • Rituximab

Substances

  • Aquaporin 4
  • Immunologic Factors
  • Rituximab